Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study
Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…Abstract Number: 1802 • 2018 ACR/ARHP Annual Meeting
Behcet’s Disease in the Southwestern United States
Background/Purpose: Behcet’s disease (BD) in the US is estimated to have a prevalence of 5.2-6.6 per 100,000 populations which is similar to that of European…Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…Abstract Number: 149 • 2018 ACR/ARHP Annual Meeting
Deep Immune-Profiling of CD4+ T Cells in Behçet’s Disease
Background/Purpose: Functionality and immune-phenotypes of the human CD4+ T-cell compartment in Behçet’s disease (BD) are under-investigated, but several lines of evidence point to its relevance…Abstract Number: 1804 • 2018 ACR/ARHP Annual Meeting
Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease
Background/Purpose: Uveitis is the most common ocular manifestation in Behçet Disease (BD), which can cause irreversible blindness. Once the efficacy, safety and cost-effectiveness of Adalimumab…Abstract Number: 2993 • 2018 ACR/ARHP Annual Meeting
Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis
Background/Purpose: Behçet's Syndrome (BS) is a vasculitic process which is characterized by recurrent oral and genital aphthous ulcerations, ocular, vascular, neurological, and gastrointestinal involvement .…Abstract Number: 1150 • 2017 ACR/ARHP Annual Meeting
Ocular Involvement Is Exclusive with Genital Ulcer and Skin Lesion in the Early Phase of Behçet’s Disease: Nationwide Japanese Registration.
Background/Purpose: Behçetfs disease (BD) is a chronic inflammatory syndrome with features of multi-organ involvement and presents with mucocutaneous and ocular symptoms. We have previously found…Abstract Number: 1151 • 2017 ACR/ARHP Annual Meeting
Clinical Manifestations of BehçEt’s Disease Depending on Sex and Age: Nationwide Japanese Registration
Background/Purpose: Behçetfs disease (BD) has a broad spectrum of clinical phenotypes. Sex differences in BD presentation has been one of the major topics of BD…Abstract Number: 1170 • 2017 ACR/ARHP Annual Meeting
High Output Flow Cytometry Array Classifies Subjects with Uveitis Due to Behcet’s Disease and Sarcoidosis
Background/Purpose: The information content of multi-parametric flow cytometry-based immune-phenotyping experiments is routinely underexploited given the paucity of adequate tools and strategies for large-scale unbiased data…Abstract Number: 2102 • 2017 ACR/ARHP Annual Meeting
The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria
Background/Purpose: In Japan, we have a criteria for BD since 1988. (International Journal of Tissue Reactions. 1988: 10; 59-65.) In Japanese patients diagnosed according to…Abstract Number: 2721 • 2017 ACR/ARHP Annual Meeting
Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to extraocular manifestations due to Behçet’s disease (BD). Methods: Multicenter study of patients…Abstract Number: 2722 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases
Background/Purpose: Uveitis is a severe manifestation of Behçet Disease (BD). The treatment is based on corticosteroids and conventional immunosuppressive drugs. In refractory cases, anti-TNFα had…Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…Abstract Number: 2724 • 2017 ACR/ARHP Annual Meeting
Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases
Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting
Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »